BioCryst Pharmaceuticals Inc BCRX

Healthcare Biotechnology

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.

NDAQ:BCRX - Post by User

BioCryst Pharmaceuticals Inc > This is a long term hold for me

<< Previous

Bullboard Posts

Next >>

Post by mevanion Dec 08, 2020 8:22am

265 Views

Post# 32056360

This is a long term hold for me

I haven't sold a single share and I will hold through 2021 until the catalysts play out. The risk reward scenereo here is just incredible.
We have been waiting a long time to get here. I suspect some consolidation to take place at some point here but for now it looks good.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario